The Clinical Features, Diagnosis and Management of Recurrent Thymoma

Overview

Journal J Cardiothorac Surg

Publisher Biomed Central

Specialties Cardiology & Vascular Diseases
General Surgery
Pulmonary Medicine

Date 2016 Sep 2

PMID 27580949

Citations 21

Authors

Taobo Luo

Hongguang Zhao

Xinming Zhou

Affiliations

Soon will be listed here.

Abstract

Thymoma is a disease with malignant potential, which has a recurrence rate after complete resection ranging from 5 to 50 %. Multiple studies on the risk factors, treatment or prognosis have been reported. Many of them are controversial, however. In this review, we summarized some accepted risk factors, means of diagnosis and different treatments of recurrent thymoma. The risk factors of recurrent thymoma haven't been well-studied, and its management remains controversial. We reviewed the literatures and found some key points which should be noticed during the surgery of initial thymoma. Although reoperation should be taken into account preferentially, multimodal treatments are also available. The prognosis are also been discussed.

Citing Articles

Effectiveness of Adjuvant Chemo- and Radiotherapy in Thymic Carcinoma Stage II: A Systematic Review and Meta-Analysis.

Nazzal A, Yayan J, Biancosino C, Tabatabaei S, Hekmat K Cancer Control. 2025; 31:10732748241292781.

PMID: 39865594 PMC: 11503756. DOI: 10.1177/10732748241292781.

Ansari A, Koi T, Lief S, Patibandla S, Bhatt N, Gulraiz A Cureus. 2024; 16(8):e68027.

PMID: 39347290 PMC: 11431129. DOI: 10.7759/cureus.68027.

[Clinical characteristics and prognosis of 21 patients with thymoma-associated pure red cell aplasia].

Zhang T, Zhao Y, Li L, Wang H, Song J, Wu Y Zhonghua Xue Ye Xue Za Zhi. 2024; 44(12):1031-1034.

PMID: 38503528 PMC: 10834874. DOI: 10.3760/cma.j.issn.0253-2727.2023.12.011.

Thymoma: An Overview.

Alqaidy D Diagnostics (Basel). 2023; 13(18).

PMID: 37761349 PMC: 10527963. DOI: 10.3390/diagnostics13182982.

Anterior mediastinal tumor surgery applying single-port thoracoscopy using the subxiphoid approach.

Chen H, Xu B, Zhang Q, Chen P, Cai M, Yao J Turk Gogus Kalp Damar Cerrahisi Derg. 2023; 31(2):239-248.

PMID: 37484634 PMC: 10357856. DOI: 10.5606/tgkdc.dergisi.2023.23455.

References

Singhal S, Shrager J, Rosenthal D, LiVolsi V, Kaiser L . Comparison of stages I-II thymoma treated by complete resection with or without adjuvant radiation. Ann Thorac Surg. 2003; 76(5):1635-41. DOI: 10.1016/s0003-4975(03)00819-1. View

Venuta F, Rendina E, Longo F, De Giacomo T, Anile M, Mercadante E . Long-term outcome after multimodality treatment for stage III thymic tumors. Ann Thorac Surg. 2003; 76(6):1866-72. DOI: 10.1016/s0003-4975(03)01020-8. View

Azad A, Herbertson R, Pook D, White S, Mitchell P, Tebbutt N . Motesanib diphosphate (AMG 706), an oral angiogenesis inhibitor, demonstrates clinical efficacy in advanced thymoma. Acta Oncol. 2008; 48(4):619-21. DOI: 10.1080/02841860802495362. View

Wright C, Wain J, Wong D, Donahue D, Gaissert H, Grillo H . Predictors of recurrence in thymic tumors: importance of invasion, World Health Organization histology, and size. J Thorac Cardiovasc Surg. 2005; 130(5):1413-21. DOI: 10.1016/j.jtcvs.2005.07.026. View

Palmieri G, Merola G, Federico P, Petillo L, Marino M, Lalle M . Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs). Ann Oncol. 2009; 21(6):1168-1172. DOI: 10.1093/annonc/mdp483. View

Huang J, Rizk N, Travis W, Riely G, Park B, Bains M . Comparison of patterns of relapse in thymic carcinoma and thymoma. J Thorac Cardiovasc Surg. 2009; 138(1):26-31. PMC: 4151511. DOI: 10.1016/j.jtcvs.2009.03.033. View

Krenning E, Kwekkeboom D, Bakker W, Breeman W, Kooij P, Oei H . Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993; 20(8):716-31. DOI: 10.1007/BF00181765. View

Juel V . Myasthenia gravis: management of myasthenic crisis and perioperative care. Semin Neurol. 2004; 24(1):75-81. DOI: 10.1055/s-2004-829595. View

Giaccone G, Rajan A, Berman A, Kelly R, Szabo E, Lopez-Chavez A . Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J Clin Oncol. 2011; 29(15):2052-9. PMC: 3107761. DOI: 10.1200/JCO.2010.32.4467. View

10.

Sandri A, Cusumano G, Lococo F, Alifano M, Granone P, Margaritora S . Long-term results after treatment for recurrent thymoma: a multicenter analysis. J Thorac Oncol. 2014; 9(12):1796-804. DOI: 10.1097/JTO.0000000000000370. View

11.

Fornasiero A, Daniele O, Ghiotto C, Piazza M, FIORE-DONATI L, Calabro F . Chemotherapy for invasive thymoma. A 13-year experience. Cancer. 1991; 68(1):30-3. DOI: 10.1002/1097-0142(19910701)68:1<30::aid-cncr2820680106>3.0.co;2-4. View

12.

VERLEY J, HOLLMANN K . Thymoma. A comparative study of clinical stages, histologic features, and survival in 200 cases. Cancer. 1985; 55(5):1074-86. DOI: 10.1002/1097-0142(19850301)55:5<1074::aid-cncr2820550524>3.0.co;2-t. View

13.

Bott M, Wang H, Travis W, Riely G, Bains M, Downey R . Management and outcomes of relapse after treatment for thymoma and thymic carcinoma. Ann Thorac Surg. 2011; 92(6):1984-91. DOI: 10.1016/j.athoracsur.2011.07.078. View

14.

Kondo K, Monden Y . Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann Thorac Surg. 2003; 76(3):878-84; discussion 884-5. DOI: 10.1016/s0003-4975(03)00555-1. View

15.

Wright C . Management of thymomas. Crit Rev Oncol Hematol. 2007; 65(2):109-20. DOI: 10.1016/j.critrevonc.2007.04.005. View

16.

Huang J, Rizk N, Travis W, Seshan V, Bains M, Dycoco J . Feasibility of multimodality therapy including extended resections in stage IVA thymoma. J Thorac Cardiovasc Surg. 2007; 134(6):1477-83. DOI: 10.1016/j.jtcvs.2007.07.049. View

17.

Hamaji M, Allen M, Cassivi S, Nichols 3rd F, Wigle D, Deschamps C . The role of surgical management in recurrent thymic tumors. Ann Thorac Surg. 2012; 94(1):247-54. DOI: 10.1016/j.athoracsur.2012.02.092. View

18.

Loehrer Sr P, Chen M, Kim K, Aisner S, Einhorn L, Livingston R . Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. J Clin Oncol. 1997; 15(9):3093-9. DOI: 10.1200/JCO.1997.15.9.3093. View

19.

Maggi G, Casadio C, Cavallo A, Cianci R, Molinatti M, Ruffini E . Thymoma: results of 241 operated cases. Ann Thorac Surg. 1991; 51(1):152-6. DOI: 10.1016/0003-4975(91)90478-9. View

20.

Palmieri G, Marino M, Salvatore M, Budillon A, Meo G, Caraglia M . Cetuximab is an active treatment of metastatic and chemorefractory thymoma. Front Biosci. 2006; 12:757-61. DOI: 10.2741/2098. View